TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32376724
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg orally once daily) plus Camrelizumab (200 mg intravenously every 2 weeks)
Study: 34878650
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (Anakinra)
Study: 33185373
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block using 25 mg bupivacaine plus 8 mg dexamethasone in a total volume of 10 mL twice one week apart (Group I)
Study: 33185373
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block using 25 mg bupivacaine plus 8 mg dexamethasone in a total volume of 10 mL 3 times one week apart (Group II)
Study: 34996406
Drug: Liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3 mg daily injection
Study: 35590219
Drug: PF-06835919 300
Normalized name: filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-06835919 300 mg
Study: 35590219
Drug: PF-06835919 75
Normalized name: PF-06835919
DrugBank: PF-06835919 (DB19163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06835919 75 mg
Study: 33542908
Drug: 18-22 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18-22 mg/kg/d UDCA
Study: 33542908
Drug: 13-15 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-15 mg/kg/d UDCA (standard dosage)
Study: 34837744
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2)
Study: 34837744
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 6) and paclitaxel (175 mg/m2) without bevacizumab
Study: 33874974
Drug: VR based
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR based intervention along with standard treatment
Study: 33874974
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment after surgery (control group)
Study: 32571411
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical acupoint stimulation (TEAS) for 30 min at four acupoints, 4 times weekly for 12 weeks (total of 48 sessions)
Study: 37728406
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) therapy
Study: 35089798
Drug: Intensive versus
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive versus standard blood pressure treatment
Study: 36329080
Drug: Micronutrients as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrients as nanoparticles (MN‐NPs) at a concentration of 40 mg/L
Study: 36329080
Drug: Micronutrients as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrients as nanoparticles (MN‐NPs) at concentrations of 0, 10, 20, 30 mg/L
Study: 32250061
Drug: 1.5 mm
Normalized name: blade lancet, safety 1.5 mm X 2 mm MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mm subcrestally placed implants
Study: 32250061
Drug: Epicrestally placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epicrestally placed implants with 2 mm healing abutment
Study: 35379638
Drug: HUC-MSCs administered
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HUC-MSCs administered intravenously at a dose of 1×10^6 cells/kg with a total volume of 100 mL diluted with normal saline through 120 mL/hour intravenous central line infusion
Study: 35379638
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered through 120 mL/hour intravenous central line infusion at the same quantity (total volume of 100 mL)
Study: 34441048
Drug: Lactoferrin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin treatment for seven days
Study: 35396667
Drug: favipiravir treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: favipiravir treatment (early treatment group on day 1)
Study: 35396667
Drug: favipiravir treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: favipiravir treatment (late treatment group on day 6)
Study: 34333820
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg liquid (extracted from capsules)
Study: 34333820
Drug: Enzalutamide 40
Normalized name: enzalutamide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide 40 mg liquid-filled soft-gelatin capsules (commercially available)
Study: 34963639
Drug: Co-Administered RZV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-Administered RZV and PCV13 (N=449)
Study: 34963639
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sequential administration of PCV13 and RZV) (N=463)
Study: 33827392
Drug: Psychological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapy for depression
Study: 32460801
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g HMB + 5 g creatine per day (HMB-Cr)
Study: 32460801
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g creatine + 5 g placebo per day (Cr)
Study: 33934703
Drug: Fixed GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed GnRH antagonist protocol (ganirelix 0.25 mg/d started on day 5)
Study: 33934703
Drug: Flexible GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible GnRH antagonist protocol (started when LH > 10 IU/L, follicle > 12 mm, or serum E2 > 600 pg/ml)
Study: 33059886
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intensive lifestyle modification and oral contraceptive pills (Combined)
Study: 35238148
Drug: Topical ascorbic
Normalized name: ascorbic acid Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ascorbic acid (AA) application
Study: 32990349
Drug: Rotating antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotating antibiotics for 6 weeks in conjunction with darifenacin for 6 months
Study: 36216304
Drug: Calcitriol 0.25
Normalized name: CALCITRIOL 0.25MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.25 μg once daily
Study: 36149628
Drug: Combined intracervical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intracervical foley's catheter plus intravenous oxytocin infusion
Study: 36070433
Drug: Maitake D-Fraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maitake D-Fraction (4 capsules, 3 times a day, taken orally before meals)
Study: 37874111
Drug: Pioglitazone tablet
Normalized name: Pioglitazone Tablets
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone tablet
Study: 35477413
Drug: Narrative Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Exposure Therapy for Children (KIDNET)
Study: 34636474
Drug: Transoral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral injection with hyaluronic acid
Study: 33682145
Drug: Acetate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate infusion
Study: 32644127
Drug: KAF156 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 800 mg
Study: 32644127
Drug: KAF156 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 50 mg
Study: 32644127
Drug: KAF156 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 300 mg
Study: 32644127
Drug: KAF156 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 100 mg
Study: 32644127
Drug: KAF156 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 20 mg
Study: 35900313
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) at doses of 25, 100, 200, 400, and 800 µg/day
Study: 35900313
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) at doses of 50, 200, 500, 1000, and 2000 µg/day
Study: 35900313
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) at doses of 100, 400, 800, 1600, and 3200 µg/day
Study: 35900313
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) at therapeutic doses
Study: 35900313
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) at therapeutic doses
Study: 35900313
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) at therapeutic doses
Study: 35900313
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) at highest/supratherapeutic doses
Study: 35900313
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) at highest/supratherapeutic doses
Study: 35900313
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) at comparable therapeutic doses (100 µg/day)
Study: 36054180
Drug: Incremental loop
Normalized name: LOOP OSTOMY ROD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental loop diuretic dose titration after >24 h
Study: 33658762
Drug: Retinol palmitate
Normalized name: Retinol palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinol palmitate ophthalmic solution
Study: 35743694
Drug: Balanced crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid solution (Optilyte®) 20 mL/kg
Study: 35743694
Drug: Gelatine 26.500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine 26.500 Da (Geloplasma®) 20 mL/kg
Study: 33125516
Drug: Vericiguat 0.5–15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 0.5–15.0 mg solution (first‐in‐human study) or 1.25–10.0 mg immediate release (IR tablets) single dose
Study: 33125516
Drug: Vericiguat 1.25–10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 1.25–10.0 mg IR tablets once daily (QD) or 5.0 mg IR tablets twice daily for 7 consecutive days
Study: 33125516
Drug: Vericiguat 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 5.0 mg IR tablets with food
Study: 33125516
Drug: Vericiguat 15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 15.0 mg (oral solution, fasted)
Study: 33125516
Drug: Vericiguat ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat ≤ 10.0 mg, IR tablets
Study: 32176711
Drug: Oral Antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Antithrombotic Treatment (OAT)
Study: 32176711
Drug: Phenprocoumon or
Normalized name: phenprocoumon Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenprocoumon or Warfarin
Study: 36060518
Drug: CABG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CABG plus Medical therapy (CABG + MED)
Study: 34793868
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 10 mg once daily
Study: 34793868
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 25 mg once daily
Study: 36078394
Drug: Chuna manual
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuna manual therapy + usual care
Study: 34901915
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy (AIT)
Study: 35850367
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea treatment
Study: 35850367
Drug: Tannic acid
Normalized name: Tannic Acid
DrugBank: Tannic acid (DB09372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tannic acid treatment
Study: 32221489
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MINB and IANB
Study: 36030106
Drug: 1PC111 (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1PC111 (fixed-dose combination of pitavastatin 2 mg and ezetimibe 10 mg)
Study: 36030106
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg)
Study: 34344286
Drug: Pharmacotherapy rotation
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy rotation (PTR)
Study: 36191669
Drug: 400 g
Normalized name: Ambi 60 PSE-400 GFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 g portion size
Study: 36191669
Drug: 500 g
Normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 g portion size
Study: 36191669
Drug: 600 g
Normalized name: PETROLATUM 600 g in 1000 g TOPICAL OINTMENT [EltaMD Laser Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 g portion size
Study: 36191669
Drug: 700 g
Normalized name: ISOPROPYL ALCOHOL 700 g in 1000 g TOPICAL SOLUTION [GERMSTARORIGINAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 g portion size
Study: 34197792
Drug: Self-administered interRAI
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered interRAI Check-Up Assessment (CUSR)
Study: 35569035
Drug: Higher-dose combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose combination group (180 μg albuterol and 160 μg budesonide)
Study: 35569035
Drug: Lower-dose combination
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose combination group (180 μg albuterol and 80 μg budesonide)
Study: 35569035
Drug: Albuterol-alone group
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol-alone group (180 μg albuterol)
Study: 32543684
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after 3-month DAPT (90 mg twice daily)
Study: 32682946
Drug: Posaconazole IV
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole IV 3.5, 4.5 or 6.0 mg/kg/d for ≥10 days
Study: 32682946
Drug: Posaconazole PFS
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole PFS at the identical dose for ≤18 days
Study: 34918951
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment for 26 weeks
Study: 34918951
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment for 26 weeks in nonproliferative diabetic retinopathy subgroup
Study: 34918951
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 26 weeks in nonproliferative diabetic retinopathy subgroup
Study: 34918951
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment for 26 weeks in proliferative diabetic retinopathy subgroup
Study: 34918951
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 26 weeks in proliferative diabetic retinopathy subgroup
Study: 34371826
Drug: Combined-exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-exercise program and nutrition supplement (n = 23)
Study: 35405087
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy plus bevacizumab
Study: 35405087
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel plus bevacizumab
Study: 32100261
Drug: PegIFNα-2a or
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNα-2a or PegIFNα-2b (48-week treatment)
Study: 35236650
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment alone
Study: 32795310
Drug: Canola oil
Normalized name: Canola Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canola oil (CO) 25 mL/day for 6 weeks
Study: 32795310
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (OO) 25 mL/day for 6 weeks
Study: 33506521
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy (ACT) orientated anger management training
Study: 34371884
Drug: tRES-HESP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: tRES-HESP treatment
Study: 36006634
Drug: Anti-vascular endothelial
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-vascular endothelial growth factor therapy
Study: 32248190
Drug: Inhaled tiotropium
Normalized name: tiotropium Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tiotropium (5 μg, two inhalations of 2.5 μg) for at least 2 weeks before esophagectomy and continued until postoperative evaluation
Study: 32358544
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor (empagliflozin)
Study: 34597366
Drug: Quizartinib +
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib + low-dose ara-C (LDAC)
Study: 34597366
Drug: Low-dose ara-C
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ara-C (LDAC) alone
Study: 32224420
Drug: 7-day self-reported
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day self-reported nicotine patch use
Study: 32224420
Drug: 3-week self-reported
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week self-reported nicotine patch use
Study: 32224420
Drug: 11-week self-reported
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 11-week self-reported nicotine patch use
Study: 32224420
Drug: 3-day self-reported
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day self-reported nicotine patch use
Study: 33655432
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate supplementation (220 mg/day, containing 50 mg Zn) for 8 weeks
Study: 33655432
Drug: Placebo (220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (220 mg corn starch) for 8 weeks
Study: 32485095
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 50, 125, 300, or 600 mg/week plus placebo for 20 weeks in 5aR trial
Study: 32485095
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 100 mg/week plus placebo for 6 months in OPTIMEN trial
Study: 33183908
Drug: Cannabis use
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis use during treatment
Study: 33985364
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg plus hydrochlorothiazide 12.5 mg daily (active treatment)
Study: 33985364
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg daily (active treatment)
Study: 33985364
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of candesartan plus hydrochlorothiazide and rosuvastatin (active treatment)
Study: 33201520
Drug: Org 48,775-0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 48,775-0 (30 mg)
Study: 33201520
Drug: Org 48,775-0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 48,775-0 (70 mg)
Study: 33201520
Drug: Org 48,775-0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 48,775-0 (150 mg)
Study: 33201520
Drug: Org 48,775-0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 48,775-0 (≥30 mg)
Study: 33327312
Drug: ω‐3 PUFAs,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 PUFAs, 640 mg t.i.d during chemotherapy and 1 month after treatment
Study: 35287430
Drug: Low-dose COH04S1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose COH04S1 (1·0×10^7 PFU)
Study: 35287430
Drug: Medium-dose COH04S1
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose COH04S1 (1·0×10^8 PFU)
Study: 35287430
Drug: High-dose COH04S1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose COH04S1 (2·5×10^8 PFU)
Study: 35287430
Drug: Low-dose COH04S1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose COH04S1 followed by placebo
Study: 35287430
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose levels of COH04S1
Study: 35287430
Drug: COH04S1 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: COH04S1 (any dose)
Study: 33239044
Drug: Eculizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (1200 mg) administered intravenously < 12 h, on day 3 and on day 7 after ictus, with prophylactic antibiotics for 4 weeks.